Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

This randomized, open-label, phase 2b study (NCT01565668) evaluated the efficacy and safety of 2 dosing regimens of quizartinib monotherapy in patients with relapsed/refractory (R/R) FLT3-internal tandem duplication (ITD)–mutated acute myeloid leukemia (AML) who previously underwent transplant or 1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Cortes, Jorge E., Tallman, Martin S., Schiller, Gary J., Trone, Denise, Gammon, Guy, Goldberg, Stuart L., Perl, Alexander E., Marie, Jean-Pierre, Martinelli, Giovanni, Kantarjian, Hagop M., Levis, Mark J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6085992/
https://ncbi.nlm.nih.gov/pubmed/29875101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-01-821629
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars